QNCX Quince Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: QNCX

Price (delayed)

$1.05

Market cap

$45.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.84

Enterprise value

$38.37M

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence ...

Highlights
The EPS rose by 45% year-on-year but it has declined by 11% since the previous quarter
The net income rose by 39% YoY but it fell by 12% QoQ
The quick ratio has plunged by 79% from the previous quarter and by 73% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cortexyme.com
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of QNCX
Market
Shares outstanding
43.22M
Market cap
$45.38M
Enterprise value
$38.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$31.58M
EBITDA
-$31.26M
Free cash flow
-$18.36M
Per share
EPS
-$0.84
Free cash flow per share
-$0.49
Book value per share
$1.98
Revenue per share
$0
TBVPS
$2.33
Balance sheet
Total assets
$167.9M
Total liabilities
$82.82M
Debt
$13.75M
Equity
$85.08M
Working capital
$67.87M
Liquidity
Debt to equity
0.16
Current ratio
8.09
Quick ratio
7.84
Net debt/EBITDA
0.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-28.8%
Return on equity
-36.4%
Return on invested capital
-52.8%
Return on capital employed
-19.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QNCX stock price

How has the Quince Therapeutics stock price performed over time
Intraday
-0.94%
1 week
11.36%
1 month
-13.22%
1 year
-29.05%
YTD
0%
QTD
-0.94%

Financial performance

How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$33.04M
Net income
-$31.39M
Gross margin
N/A
Net margin
N/A
The net income rose by 39% YoY but it fell by 12% QoQ
QNCX's operating income is up by 36% year-on-year but it is down by 7% since the previous quarter

Growth

What is Quince Therapeutics's growth rate over time

Valuation

What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 45% year-on-year but it has declined by 11% since the previous quarter
QNCX's P/B is 90% below its 5-year quarterly average of 5.2 and 12% below its last 4 quarters average of 0.6
The equity has decreased by 15% YoY but it has increased by 2.3% QoQ

Efficiency

How efficient is Quince Therapeutics business performance
The ROIC has increased by 45% year-on-year but it has declined by 2.5% since the previous quarter
Quince Therapeutics's ROA has increased by 38% YoY and by 4.6% from the previous quarter
The ROE has increased by 25% YoY but it has decreased by 17% QoQ

Dividends

What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QNCX.

Financial health

How did Quince Therapeutics financials performed over time
QNCX's total assets is 103% greater than its total liabilities
QNCX's total assets has soared by 97% since the previous quarter and by 62% year-on-year
The current ratio has plunged by 79% from the previous quarter and by 74% YoY
The debt is 84% lower than the equity
The equity has decreased by 15% YoY but it has increased by 2.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.